Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals touted data today from a head-to-head clinical adhesion study of its ZTlido lidocaine patch, comparing it to the EU reference product, Versatis.
ZTlido is a lidocaine patch in development for the treatment of post-herpetic neuralgia – a severe neuropathic pain condition that affects elderly people and patients who have had a Shingles infection, HIV/AIDS or cancer. The anhydrous patch contains just 36 milligrams of lidocaine, compared to Lidoderm and Versatis which each have 700 milligrams of the painkiller.
Get the full story at our sister site, Drug Delivery Business News.
The post Scilex touts head-to-head study of lidocaine pain-relief patch appeared first on MassDevice.